当前位置： SCI文献检索 > ANTIMICROBIAL AGENTS AND CHEMOTHERAPY期刊下所有文献 > Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.

Abstract：

:We assessed the activity and safety of liposomal nystatin, a broad-spectrum antifungal agent, for invasive aspergillosis in patients refractory to or intolerant of amphotericin B. Thirty-three patients were enrolled, received at least one dose of the study drug, and were evaluable for safety. Twenty-six patients had confirmed probable or definite aspergillosis and were fully eligible. Most patients had a hematological malignancy (53.8%) or hematopoietic stem cell transplantation (23.0%), were neutropenic (61.5%), and were refractory to previous amphotericin B (92.3%). The median duration of previous amphotericin B treatment was 16.5 days (range, 5 to 64 days). Aspergillosis was definite in 3 cases and probable in 23 cases. Liposomal nystatin was initiated at a dose of 4 mg/kg of body weight/day. Twenty-five patients were evaluable for response: a complete response was achieved for one patient, and a partial response was achieved for six. Thus, the overall response rate is 7 of 25 (28%; 95% confidence interval, 12 to 49%). Seventeen (68.0%) of the 25 evaluable patients died during therapy or within 1 month after the end of therapy. The primary cause of death was invasive aspergillosis for nine patients and underlying malignancy for eight patients. The most frequent side effects included chills, shivering, and fever, leading to discontinuation of therapy for two patients. Grade 1 decline in renal function was seen for 10 (30.3%) patients, and hypokalemia was seen for 13 (39.4%). We conclude that liposomal nystatin can be effective for salvage therapy of invasive aspergillosis. Infusion-related adverse events have been observed frequently.

journal_name

Antimicrob Agents Chemother

journal_title

Antimicrobial agents and chemotherapy

authors

Offner F,Krcmery V,Boogaerts M,Doyen C,Engelhard D,Ribaud P,Cordonnier C,de Pauw B,Durrant S,Marie JP,Moreau P,Guiot H,Samonis G,Sylvester R,Herbrecht R,EORTC Invasive Fungal Infections Group.

doi

10.1128/AAC.48.12.4808-4812.2004

subject

Has Abstract

pub_date

2004-12-01 00:00:00

pages

4808-12

issue

eissn

0066-4804

issn

1098-6596

pii

48/12/4808

journal_volume

pub_type

临床试验,杂志文章

在线工具

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.